Medical Device Connectivity Market: as the 21st Century Cures Act's FHIR mandate collides with a healthcare device ecosystem still running mostly on HL7 v2 messaging, connectivity platforms that can bridge both standards without breaking legacy pipelines are absorbing a disproportionate share of new hospital investment, so interoperability integration expertise, not raw device connection volume, is becoming the deciding competitive factor.

The global medical device connectivity market size was USD 5.82 Billion in 2025 and is expected to register a revenue CAGR of 14.2% during the forecast period.Market revenue growth is driven by factors such as regulatory mandates forcing a shift from proprietary device protocols to standardised interoperability, the accelerating installed base of remote patient monitoring devices, and rising board-level cybersecurity investment in connected device infrastructure.The first driving factor is the 21st Century Cures Act's standardised API mandates forcing a shift from proprietary medical device protocols to FHIR-based exchanges. Health systems that have completed interoperability compliance programmes report a 13% reduction in documentation time and improved care coordination.The second driving factor is remote patient monitoring's accelerating share of the installed connected device base. RPM accounted for over 35% of installed connected devices globally in 2025, with a 30% year-on-year increase in RPM-enabled devices.The third driving factor is rising board-level cybersecurity scrutiny following ransomware attacks on connected IoMT endpoints, creating additional demand for connectivity solutions with embedded zero-trust security architectures.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a connectivity platform that can bridge both legacy HL7 v2 messaging and modern FHIR-based APIs widens its addressable hospital footprint without requiring the hospital to rip out its existing device fleet, which converts a single integration engagement into an ongoing multi-device-generation platform relationship.Once a connectivity vendor's middleware can normalise both legacy HL7 v2 streams and new FHIR-native device data into the same EHR-ready payload, each additional device generation a hospital adds, old or new, becomes revenue captured by the same platform relationship rather than requiring a competing vendor's parallel integration, so platform revenue compounds as the hospital's device fleet grows around it regardless of which standard any individual device speaks.As a result, demand and revenue share are concentrating around connectivity platforms with genuine dual-standard bridging capability, that hold the deepest legacy-to-modern integration engineering expertise, and the forecast tilts toward these bridging platforms rather than single-standard, FHIR-only point solutions.For instance, in April 2026, HL7 launched its Device Interoperability Implementation Community, building on the Gemini Device Interoperability Program's partnership with Integrating the Healthcare Enterprise, specifically to address the persistent fragmentation between the majority of hospital device data still running on HL7 v2 and the FHIR standard that new devices increasingly speak.These are some of the key factors driving revenue growth of the market.

Because the majority of hospital device data transfer continues to run on HL7 v2 messaging rather than modern FHIR-based APIs, a single case-sensitivity error, mismatched patient identifier, or version mismatch during a system upgrade can stop entire workflow pipelines from processing messages, requiring significant integration engineering effort to maintain reliable connectivity across heterogeneous clinical environments.

Cybersecurity compliance costs are a second constraint, because FDA premarket submission cybersecurity plan and labelling disclosure requirements for network-capable devices add regulatory compliance costs and development timelines that may slow connected device launches by 6 to 18 months relative to non-connected device programmes.

Legacy equipment integration burden is a third constraint, since hospital device fleets spanning multiple technology generations require ongoing middleware maintenance investment that does not diminish even as newer FHIR-native devices are added to the same clinical environment.

These factors substantially limit medical device connectivity market growth over the forecast period.

The clearest driver of demand is the regulatory mandate forcing a nationwide shift from proprietary device protocols to a single standardised exchange format. A hospital only invests in FHIR-compliant connectivity infrastructure at scale if the regulatory penalty for non-compliance genuinely outweighs the cost of legacy system continuity, and the ONC's information blocking prohibitions, backed by the 21st Century Cures Act's statutory authority, create exactly that penalty structure for certified health information technology. The ONC's Final Rule, published as 85 FR 25642 on May 1, 2020, established HL7 FHIR as the nationwide standard for access, exchange, and use of health information data, mandating SMART/HL7 FHIR Bulk Data API support as a universal requirement for ONC-certified health information technology by December 31, 2022. In January 2025, Silex Technology America launched the SX-PCEBE embedded radio module supporting Wi-Fi CERTIFIED 7 and Bluetooth 5.3, positioning itself as a next-generation connectivity component purpose-built for FHIR-compliant medical device integration. The effect on the market is that device manufacturers and hospitals face a hard compliance deadline that is compressing what would otherwise be a gradual, multi-year technology refresh cycle into concentrated near-term connectivity infrastructure investment. These are some of the key factors driving revenue growth of the market.

The second driver is the sheer scale of the remote patient monitoring installed base relative to every other connectivity application. A connectivity platform only captures durable recurring revenue if its addressable device volume keeps growing after initial hospital deployment, and RPM's 30% year-on-year growth in installed connected devices means platforms serving RPM applications capture a continuously expanding device count rather than a one-time hospital-wide integration project. Remote patient monitoring accounted for over 35% of installed connected devices globally in 2025, with hospitals adopting advanced connectivity solutions reporting a 27% reduction in patient monitoring errors, providing a clinical evidence-based return-on-investment case for continued connectivity infrastructure spending. In 2025, Philips and Masimo announced a multi-year renewal and expansion of their strategic partnership integrating Masimo's SET pulse oximetry and Radius PPG monitoring technologies into Philips multi-parameter patient monitors, with the companies also developing next-generation AI-based monitoring technologies together. The effect on the market is that RPM's expanding installed base is functioning as a durable, self-reinforcing demand engine for connectivity infrastructure that grows independently of new hospital construction or capital equipment cycles. These are some of the key factors driving revenue growth of the market.

“Remote patient monitoring accounted for over 35% of installed connected medical devices globally in 2025, with RPM-enabled device counts growing 30% year-on-year, establishing RPM as the primary volume use case for connectivity infrastructure investment.”

The third driver is the shift of medical device cybersecurity from a compliance afterthought to a board-level risk management priority. A hospital only invests in embedded zero-trust connectivity architecture if the demonstrated risk of a connected-device breach genuinely threatens patient safety and institutional liability, and ransomware attacks on infusion pumps and cardiology monitors in 2024 provided exactly that demonstrated risk at a scale that elevated the issue to board-level attention. The FDA's December 2022 omnibus appropriations bill provisions require premarket submission cybersecurity plans and labelling disclosures for all new network-capable medical devices, adding regulatory compliance costs that may slow connected device launches by 6 to 18 months relative to non-connected programmes. On June 27, 2025, the FDA issued its final guidance, Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions, superseding the 2023 version and adding new recommendations addressing section 524B of the FD&C Act for cyber devices. The effect on the market is that connectivity vendors with embedded, FDA-guidance-aligned security architecture are capturing a growing share of hospital procurement budgets specifically allocated to cybersecurity risk reduction, separate from general connectivity infrastructure spending. These are some of the key factors driving revenue growth of the market.

However, the medical device connectivity market faces severe adoption constraints from persistent interoperability fragmentation and rising cybersecurity compliance costs.

Because the majority of hospital device data transfer continues to run on HL7 v2 messaging rather than modern FHIR-based APIs, a single case-sensitivity error, mismatched patient identifier, or version mismatch during a system upgrade can stop entire workflow pipelines from processing messages, requiring significant ongoing integration engineering effort across heterogeneous clinical environments spanning multiple technology generations.

Cybersecurity compliance costs compound this, because the FDA's premarket submission cybersecurity plan and labelling disclosure requirements for network-capable devices, further strengthened by the June 2025 final guidance, add regulatory compliance costs and development timelines that may slow connected device market launches by 6 to 18 months relative to non-connected device programmes.

Legacy equipment integration burden is the third constraint, since hospital device fleets spanning multiple technology generations require ongoing middleware maintenance investment that does not diminish even as newer FHIR-native devices are added, so the cost of maintaining connectivity across a hospital's full device fleet is not fully recovered even as new standards are adopted.

These factors substantially limit medical device connectivity market growth over the forecast period.

Based on component, the global medical device connectivity market is segmented into connectivity solutions and connectivity services. Connectivity solutions hold the largest revenue share at approximately 63% of 2025 revenue, because normalising heterogeneous device data across HL7v2, FHIR, and proprietary data streams into EHR-ready payloads is the core infrastructure function every connected hospital ultimately requires. Connectivity services are expected to register the fastest revenue growth rate over the forecast period, at more than 25% CAGR, driven by hospitals requiring ongoing integration engineering, middleware maintenance, and cybersecurity compliance support beyond initial solution deployment.

Based on application, the global medical device connectivity market is segmented into remote patient monitoring, hospital bedside monitoring, chronic disease management, surgical robotics and diagnostic imaging, and point of care. Remote patient monitoring holds a significantly large revenue share, accounting for over 35% of installed connected devices globally, reflecting the post-pandemic acceleration in home-based and telehealth-supported care delivery. Chronic disease management, spanning continuous glucose monitoring, cardiac monitoring, and home care applications, is expected to register the fastest revenue growth rate, driven by expanding connected CGM and cardiac device adoption at platforms including Philips and Masimo.

Based on technology, the global medical device connectivity market is segmented into wired, wireless, cellular, and satellite connectivity. Wireless connectivity, spanning Wi-Fi, Bluetooth, Zigbee, and 5G, holds the largest revenue share, because most new connected device designs prioritise wireless integration for patient mobility and clinical workflow flexibility over fixed wired connections. Cellular connectivity, including 5G private network and IoMT applications, is expected to register the fastest revenue growth rate, driven by hospital 5G private network deployments and expanding RPM device cellular connectivity requirements independent of home Wi-Fi availability.

Based on regional analysis, the medical device connectivity market in North America accounted for largest revenue share in 2025. The United States leads because the 21st Century Cures Act's ONC Final Rule creates a binding regulatory compliance deadline for interoperability, and because the country hosts the headquarters or primary operations of Baxter, Philips North America, GE HealthCare, and Masimo, the largest connectivity solution providers serving the US hospital base. Hospitals adopting advanced connectivity solutions reported a 27% reduction in patient monitoring errors across US healthcare facilities, providing the clinical evidence base supporting continued US connectivity infrastructure investment. The concentration of ONC-certified connectivity vendors in the United States also means new interoperability standards and FHIR implementation approaches are often piloted domestically before being extended to other regions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, France, and the Netherlands represent the four largest national markets, with Germany's Krankenhauszukunftsgesetz digital investment programme accelerating HL7-FHIR gateway procurement at German hospital systems. The UK NHS mandates digital maturity assessments for NHS trusts that unlock funding for secure device onboarding and connectivity infrastructure, but fragmented national funding programmes and hospital-by-hospital digital maturity variation create uneven adoption pacing across the region. The result is steady rather than rapid growth, shaped more by national digital investment programme timing than by underlying clinical demand.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period, driven by China, Japan, South Korea, and India's expanding hospital digitisation investment and growing RPM adoption for chronic disease management at scale. China's rapid hospital digital infrastructure build-out and Japan's ageing population driving home-based chronic disease monitoring demand are the region's two largest growth contributors. This leaves more room for growth than in the more mature North American and European connectivity markets, where hospital-vendor relationships are already largely established.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets, with connectivity infrastructure investment concentrated at private hospital networks in São Paulo and Mexico City. Iran-US sanctions continue to disrupt freight and import costs for the specialised networking hardware, embedded radio modules, and cellular connectivity components that Latin American hospital systems depend on, with cargo rerouting around the Strait of Hormuz corridor raising landed component costs and slowing connectivity infrastructure expansion beyond the region's main hospital networks through 2026.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary GCC commercial markets, with the Saudi Vision 2030 healthcare digitisation programme driving new demand for hospital connectivity infrastructure. The UAE is the most established market on the continent for hospital-wide connectivity infrastructure, while the Gulf states more broadly are still building digital hospital infrastructure largely from scratch.